Weastfinace Group

Westlake Therapeutics is a clinical-stage biotechnology company specializing in the development of innovative red blood cell (RBC) based therapies. As the first spinoff from Westlake University, the company utilizes its proprietary REDx platform to engineer natural erythrocytes for the delivery of various drug modalities, including antibodies and enzymes. Its lead candidate, WTX-212, is an erythrocyte-anti-PD-1 antibody conjugate currently in Phase 1 clinical trials for the treatment of advanced solid tumors and lymphomas, particularly in patients resistant to standard checkpoint inhibitors. The company's pipeline also extends to metabolic and rare diseases, with programs targeting refractory gout and thrombosis. Westlake Therapeutics operates its own manufacturing facility in Shanghai to support its clinical and future commercial needs.